당뇨병 치료제 시장 : 시장 인사이트, 경쟁 구도, 시장 예측(2032년)

Diabetes Drugs Market Summary

• The global diabetes drugs market is expected to increase from USD 109,726.82 million in 2025 to USD 321,143.29 million by 2034, reflecting strong and sustained growth.
• The global diabetes drugs market is growing at a CAGR of 12.76% during the forecast period from 2026 to 2034.
• The overall diabetes drug market is experiencing substantial growth due to a combination of several key factors. The increasing prevalence of diabetes worldwide, driven by lifestyle changes, obesity, and genetic predisposition, has created a strong demand for effective therapies to manage blood sugar levels and prevent complications. Alongside this, growing awareness among patients and healthcare professionals about the importance of early diagnosis, continuous monitoring, and maintaining optimal glycemic control is encouraging better treatment adherence and timely intervention. At the same time, key market players are actively investing in research and development, resulting in the launch of new and advanced insulin formulations, non-insulin therapies, and combination drugs that offer improved efficacy, safety, and convenience for patients. These innovations, coupled with educational initiatives and patient support programs, are expanding treatment options and accessibility, collectively driving the overall growth and dynamism of the diabetes drug market.
• The leading companies operating in the diabetes drugs market include Novo Nordisk A/S, Eli Lilly and Company, AstraZeneca, Sanofi, Merck & Co., Inc., Novartis AG, Johnson & Johnson Services Inc., Takeda Pharmaceutical Company, Bayer AG, Pfizer Inc., Boehringer Ingelheim, MannKind Corporation, Bain Capital (Mitsubishi Tanabe Pharma Corporation (MTPC)), Gan & Lee Pharmaceuticals, Biocon Limited, TheracosBio, LLC, Sun Pharmaceutical Industries, Cadila Pharmaceuticals, Glenmark Pharmaceuticals, Hangzhou Sciwind Biosciences Co., Ltd., and others.
• North America is expected to dominate the Diabetes Drugs market due to the high prevalence of diabetes, strong presence of leading pharmaceutical companies, advanced healthcare infrastructure, and increasing adoption of innovative therapies such as GLP-1 receptor agonists and insulin analogs. In addition, favorable reimbursement policies and rising awareness regarding diabetes management are further supporting market growth in the region.
• In the drug class segment of the diabetes drugs market, the non-insulin category is estimated to account for the largest market share in 2025.

Factors Contributing to the Growth of the Diabetes Drugs Market

• Increasing prevalence of diabetes and associated risk factors: Increasing prevalence of diabetes and associated risk factors, such as obesity, sedentary lifestyles, unhealthy dietary habits, and aging populations, are significantly driving the growth of the diabetes drugs market. The rising number of diabetic patients worldwide is increasing the demand for effective medications, advanced insulin therapies, and long-term disease management.
• Rising awareness about diabetes and maintenance of blood sugar levels: Rising awareness about diabetes and the importance of maintaining blood sugar levels is boosting the diabetes drugs market by encouraging early diagnosis, regular monitoring, and timely treatment. Increasing health education programs, digital health tools, and preventive healthcare initiatives are also driving the adoption of diabetes medications and management therapies.
• Increase in product development activities among the key market players: An increase in product development activities among key market players is driving the diabetes drugs market through the introduction of innovative therapies, advanced insulin formulations, and combination drugs. Continuous investments in research and development, along with a strong focus on improving treatment effectiveness and patient convenience, are further supporting market growth.

Diabetes Drugs Market Report Segmentation

This diabetes drugs market report offers a comprehensive overview of the global diabetes drugs market, highlighting key trends, growth drivers, challenges, and opportunities. It covers detailed market segmentation by Drug Type (Insulin, Non-Insulin Drugs, and Combination Drugs), Route of Administration (Oral, Intravenous, and Subcutaneous), Distribution Channel (Hospital and Retail Pharmacies and Online Pharmacies), and geography. The report provides valuable insights into the competitive landscape, regulatory environment, and market dynamics across major markets, including North America, Europe, and Asia-Pacific. Featuring in-depth profiles of leading industry players and recent product innovations, this report equips businesses with essential data to identify market potential, develop strategic plans, and capitalize on emerging opportunities in the rapidly growing Diabetes Drugs market.

Diabetes drugs are medications used to control blood glucose levels in people with diabetes by increasing insulin availability, improving insulin action, reducing glucose production, or enhancing glucose excretion, thereby helping prevent long-term complications of the disease.

The overall diabetes drugs market is experiencing substantial growth due to a combination of several important factors. The rapidly increasing prevalence of diabetes worldwide, largely driven by sedentary lifestyles, rising obesity rates, unhealthy dietary habits, aging populations, and genetic predisposition, has significantly increased the demand for effective treatment options to manage blood glucose levels and reduce diabetes-related complications. In addition, growing awareness among patients, healthcare providers, and governments regarding the importance of early diagnosis, routine monitoring, and proper glycemic control is encouraging timely treatment initiation and improved adherence to prescribed therapies.

Furthermore, leading pharmaceutical companies are continuously investing in research and development activities to introduce innovative diabetes treatments, including advanced insulin analogs, GLP-1 receptor agonists, SGLT2 inhibitors, oral antidiabetic drugs, and combination therapies that provide enhanced efficacy, improved safety profiles, and greater patient convenience. The increasing adoption of digital health technologies, continuous glucose monitoring systems, and patient support programs is also improving disease management and treatment outcomes. Moreover, supportive government initiatives, expanding healthcare access, and favorable reimbursement policies in several countries are further contributing to market expansion. Collectively, these factors are strengthening the growth trajectory and competitive landscape of the global diabetes drugs market.

What are the latest diabetes drugs market dynamics and trends?

The increasing prevalence of diabetes and its associated risk factors is a major force boosting the overall diabetes drugs market, as more people require long-term and often lifelong treatment. Rising rates of obesity, sedentary lifestyles, unhealthy diets, urbanization, aging populations, genetic predisposition, and stress are driving a steady growth in both Type 2 diabetes and, to a lesser extent, Type 1 diabetes across developed and emerging economies.

According to the latest data provided by the Diabetes Atlas (2025), the total number of people living with diabetes was 588.7 million in 2024, and the projections were further estimated to increase by 82.5 million by 2050. Additionally, as per the same source, the global prevalence of diabetes in 2024 was 11.1% and the projection further estimates that this prevalence would rise upto 13% by 2050. As diabetes is a chronic progressive condition, most patients eventually require combination therapy or insulin in addition to oral medications, thereby expanding drug utilization and market demand.

Additionally, several high-profile diabetes awareness initiatives in recent years have played an important role in expanding the diabetes drugs market by improving public understanding of the condition, promoting early diagnosis, and encouraging sustained long-term treatment. One of the most prominent global efforts is World Diabetes Day, observed every year on 14 November and jointly led by the World Health Organization (WHO) and the International Diabetes Federation (IDF), which in 2025 focused on the theme "Diabetes across life stages," drawing attention to integrated prevention, management, and self-care across all age groups and life stages. This campaign reaches audiences worldwide and encourages regular screening and better glycemic control, ultimately increasing demand for medications and diabetes care products.

In parallel, initiatives such as the Global Diabetes Walk bring communities together to promote physical activity and lifestyle changes that emphasize blood sugar management while raising awareness of diabetes risks and treatment needs.

At the national level, targeted awareness campaigns like Sun Pharma's #SeeBeyondSugar in India educate the public about diabetic complications such as retinopathy and the importance of comprehensive diabetes management beyond sugar levels, driving screening and treatment. These programs, backed by digital outreach, educational resources, screening events, and advocacy efforts, help more people understand their risk, seek timely medical advice, and adhere to prescribed drug therapies. As a result, increased awareness correlates with higher diagnosis rates and greater uptake of diabetes medications and advanced therapies, thereby supporting growth in the overall diabetes drug market.

Furthermore, the increasing product development activities among key market players are significantly boosting the overall diabetes drugs market by driving innovation, expanding therapeutic options, and improving clinical outcomes. Major pharmaceutical companies are heavily investing in research and development to introduce novel drug classes, advanced combination therapies, and next-generation formulations that offer superior glycemic control along with added cardiovascular and renal benefits.

In February 2026, MannKind Corporation announced that the first patient had been enrolled in INHALE-1ST, a clinical study evaluating the initiation of Afrezza(R) (insulin human) Inhalation Powder shortly after a type 1 diabetes diagnosis in pediatric patients.

In January 2026, the US Food and Drug Administration (FDA) accepted for priority review the supplemental biologic license application (sBLA) for Tzield (teplizumab-mzwv) to expand the current age indication from eight years and above to as young as one year old and above to delay the onset of stage 3 type 1 diabetes (T1D) in patients diagnosed with stage 2 T1D. Thus, the factors mentioned above are expected to boost the overall market of diabetes drugs during the forecast period.

However, the risk of side effects and safety concerns associated with diabetes drugs, including hypoglycemia, gastrointestinal complications, weight gain, and cardiovascular risks, is acting as a major limiting factor for market growth. In addition, stringent regulatory approval processes and strict reimbursement controls in several countries can delay product launches and limit patient access to advanced therapies, thereby restraining the growth of the diabetes drugs market.

Diabetes Drugs Market Segment Analysis

Diabetes Drugs Market by Drug Type (Insulin, Non-Insulin Drugs, and Combination Drugs), Route of Administration (Oral, Intravenous, and Subcutaneous), Distribution Channel (Hospital and Retail Pharmacies and Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

Diabetes Drugs Market Regional Analysis

North America Diabetes Drugs Market Trends

North America is expected to account for the highest proportion of 43.19% of the diabetes drugs market in 2025, out of all regions. North America is expected to dominate the Diabetes Drugs market due to the high prevalence of diabetes, strong presence of leading pharmaceutical companies, advanced healthcare infrastructure, and increasing adoption of innovative therapies such as GLP-1 receptor agonists and insulin analogs. In addition, favorable reimbursement policies and rising awareness regarding diabetes management are further supporting market growth in the region.

According to the data provided by the American Diabetes Association (2025), over 40.1 million people, or 12% of the population, were living with diabetes in the United States.

Additionally, the surge in type 2 diabetes cases, largely linked to lifestyle changes, obesity, and ageing populations, has expanded demand for non-insulin therapies such as oral antidiabetics and injectable incretin-based drugs, while the growing number of advanced and uncontrolled cases continues to drive the need for insulin therapies. Higher disease prevalence also encourages intensification of treatment, including combination therapies and earlier initiation of advanced drugs, further raising market value.

Additionally, the awareness programs in the United States are boosting the diabetes drugs market by promoting early diagnosis, timely treatment initiation, and long-term disease management. Initiatives such as the CDC's National Diabetes Prevention Program, the ADA's "Know Diabetes by Heart" campaign, and National Diabetes Awareness Month educate the public about diabetes risks and symptoms while encouraging routine screening and HbA1c testing, resulting in more diagnosed patients entering and remaining in the treatment pathway.

Furthermore, the increase in product development across the region is further boosting the overall market of diabetes drugs. For instance, in December 2024, the U.S. Food and Drug Administration approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter, a glucagon-like peptide-1 (GLP-1) receptor agonist indicated to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes as an adjunct to diet and exercise.

Thus, the factors mentioned above are expected to boost the overall market of diabetes drugs during the forecast period in the United States.

Europe Diabetes Drugs Market Trend

Europe holds the second-largest share of the market after North America, accounting for approximately 28.39% of the global market share in 2025. The diabetes drugs market in Europe is witnessing strong and sustained growth due to the rising prevalence of type 1 and type 2 diabetes, increasing obesity rates, a growing aging population, and strong awareness regarding diabetes management and preventive healthcare. According to the International Diabetes Federation (2025), the number of adults aged 20-79 with diabetes in the United Kingdom was 4.5 million in 2024, and the projection was further estimated to reach 4.9 million by 2050. The United Kingdom also had the fourth-highest number of people of all ages living with Type 1 diabetes.

The growing burden of diabetes is fueling the expansion of the diabetes drugs market by increasing the number of patients needing long-term care and treatment. Rising incidences of both Type 1 and Type 2 diabetes are driving demand for insulin, oral medications, and newer therapeutic options. Contributing factors such as early detection, an aging population, and lifestyle-related risks, including obesity and low physical activity, are further broadening the patient pool.

The region also benefits from advanced healthcare infrastructure, favorable reimbursement systems, and high adoption of innovative therapies such as GLP-1 receptor agonists and SGLT2 inhibitors. In addition, pharmaceutical companies are heavily investing in research and development activities to introduce more effective and convenient treatment options, including once-weekly injectables and oral diabetes drugs. Recent regulatory approvals are further supporting market expansion across Europe. In April 2024, the European Commission granted approval for the KwikPen presentation of Mounjaro to improve patient convenience and accessibility.

Thus, the factors mentioned above are expected to boost the overall market of diabetes drugs in Europe.

Asia-Pacific Diabetes Drugs Market Trends

Asia-Pacific is the fastest-growing region in the global diabetes drugs market and is expected to account for approximately 16.92% of the global market share in 2025. The region is emerging as a significant growth engine due to the rapidly increasing diabetic population, rising urbanization, changing dietary patterns, and the growing prevalence of obesity and sedentary lifestyles across major economies such as China, India, and Japan. Additionally, improving healthcare infrastructure, increasing healthcare expenditure, growing awareness regarding diabetes management, and expanding access to advanced antidiabetic therapies are further supporting market growth across the Asia-Pacific region. According to the International Diabetes Federation (2025), Japan was among the top ten countries globally with the highest number of adults aged 20-79 years living with diabetes. The number of adults with diabetes in Japan was estimated at approximately 10.8 million in 2024 and is projected to reach around 9.4 million by 2050.

Additionally, the increasing healthcare expenditure, improving access to diabetes diagnosis and treatment, and rising awareness regarding blood sugar management are further supporting market growth in the region. In addition, the expansion of healthcare infrastructure, growing availability of advanced insulin therapies and oral antidiabetic drugs, and supportive government initiatives for chronic disease management are accelerating the adoption of diabetes treatments. The presence of a large patient pool and increasing investments by pharmaceutical companies in the APAC region are also contributing significantly to the expansion of the diabetes drugs market.

Who are the major players in the diabetes drugs market?

The following are the leading companies in the Diabetes Drugs market. These companies collectively hold the largest market share and dictate industry trends.

• Novo Nordisk A/S
• Eli Lilly and Company
• AstraZeneca
• Sanofi
• Merck & Co., Inc.
• Novartis AG
• Johnson & Johnson Services Inc.
• Takeda Pharmaceutical Company
• Bayer AG
• Pfizer Inc
• Boehringer Ingelheim
• MannKind Corporation
• Bain Capital (Mitsubishi Tanabe Pharma Corporation (MTPC))
• Gan & Lee Pharmaceuticals
• Biocon Limited
• TheracosBio, LLC
• Sun Pharmaceutical Industries
• Cadila Pharmaceuticals
• Glenmark Pharmaceuticals
• Hangzhou Sciwind Biosciences Co., Ltd.
• Lupin Limited
• Torrent Pharmaceuticals
• Astellas Pharma Inc.
• Lexicon Pharmaceuticals
• Dong-A ST
• Hanmi Pharmaceutical
• Others

How is the competitive landscape shaping the diabetes drugs market?

The competitive landscape of the diabetes drugs market is highly dynamic and characterized by strong competition among leading pharmaceutical companies focused on innovation, strategic collaborations, product launches, and geographic expansion. Major players such as Novo Nordisk, Eli Lilly and Company, Sanofi, AstraZeneca, and Boehringer Ingelheim are heavily investing in research and development activities to introduce advanced therapies, including GLP-1 receptor agonists, SGLT2 inhibitors, long-acting insulin analogs, and combination drugs. Companies are also focusing on expanding their biologics and oral antidiabetic portfolios to strengthen market presence and improve patient convenience. In addition, partnerships, mergers, and acquisitions are helping manufacturers enhance technological capabilities and global distribution networks. The increasing competition in biosimilar insulin products and the growing adoption of personalized diabetes care solutions are further intensifying market competition, encouraging continuous innovation and pricing strategies across the global diabetes drugs market.

Recent Developmental Activities in the Diabetes Drugs Market

• In February 2026, MannKind Corporation announced that the first patient had been enrolled in INHALE-1ST, a clinical study evaluating the initiation of Afrezza(R) (insulin human) Inhalation Powder shortly after a type 1 diabetes diagnosis in pediatric patients.
• In January 2026, the US Food and Drug Administration (FDA) accepted for priority review the supplemental biologic license application (sBLA) for Tzield (teplizumab-mzwv) to expand the current age indication from eight years and above to as young as one year old and above to delay the onset of stage 3 type 1 diabetes (T1D) in patients diagnosed with stage 2 T1D.
• In January 2026, the European Commission approved Teizeild (teplizumab) to delay the onset of stage 3 type 1 diabetes (T1D) in adult and pediatric patients eight years of age and older with stage 2 T1D.

Diabetes Drugs Market Segmentation

• Diabetes Drugs by Drug Type Exposure
• Insulin
• Non-Insulin Drugs
• Combination Drugs
• Diabetes Drugs by Route of Administration Exposure
• Oral
• Intravenous
• Subcutaneous
• Diabetes Drugs Distribution Channel Exposure
• Hospital and Retail Pharmacies
• Online Pharmacies
• Diabetes Drugs Geography Exposure
• North America Diabetes Drugs Market
• United States Diabetes Drugs Market
• Canada Diabetes Drugs Market
• Mexico Diabetes Drugs Market
• Europe Diabetes Drugs Market
• United Kingdom Diabetes Drugs Market
• Germany Diabetes Drugs Market
• France Diabetes Drugs Market
• Italy Diabetes Drugs Market
• Spain Diabetes Drugs Market
• Rest of Europe Diabetes Drugs Market
• Asia-Pacific Diabetes Drugs Market
• China Diabetes Drugs Market
• Japan Diabetes Drugs Market
• India Diabetes Drugs Market
• Australia Diabetes Drugs Market
• South Korea Diabetes Drugs Market
• Rest of Asia-Pacific Diabetes Drugs Market
• Rest of the World Diabetes Drugs Market
• South America Diabetes Drugs Market
• Middle East Diabetes Drugs Market
• Africa Diabetes Drugs Market

Key takeaways from the diabetes drugs market report study

• Market size analysis for the current diabetes drugs market size (2025), and market forecast for 8 years (2026 to 2034)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the diabetes drugs market.
• Various opportunities available for the other competitors in the diabetes drugs market space.
• What are the top-performing segments in 2025? How these segments will perform in 2034?
• Which are the top-performing regions and countries in the current diabetes drugs market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for the diabetes drugs market growth in the future.

Frequently Asked Questions for the Diabetes Drugs Market

1. What is the growth rate of the diabetes drugs market?

• The diabetes drugs market is estimated to grow at a CAGR of 12.76% during the forecast period from 2026 to 2034.

2. What is the market for diabetes drugs?

• The global diabetes drugs market is expected to increase from USD 109,726.82 million in 2025 to USD 321,143.29 million by 2034.

3. Which region has the highest share in the diabetes drugs market?

• North America is expected to dominate the Diabetes Drugs market due to the high prevalence of diabetes, strong presence of leading pharmaceutical companies, advanced healthcare infrastructure, and increasing adoption of innovative therapies such as GLP-1 receptor agonists and insulin analogs. In addition, favorable reimbursement policies and rising awareness regarding diabetes management are further supporting market growth in the region.

4. What are the drivers for the diabetes drugs market?

• The overall diabetes drug market is experiencing substantial growth due to a combination of several key factors. The increasing prevalence of diabetes worldwide, driven by lifestyle changes, obesity, and genetic predisposition, has created a strong demand for effective therapies to manage blood sugar levels and prevent complications. Alongside this, growing awareness among patients and healthcare professionals about the importance of early diagnosis, continuous monitoring, and maintaining optimal glycemic control is encouraging better treatment adherence and timely intervention. At the same time, key market players are actively investing in research and development, resulting in the launch of new and advanced insulin formulations, non-insulin therapies, and combination drugs that offer improved efficacy, safety, and convenience for patients. These innovations, coupled with educational initiatives and patient support programs, are expanding treatment options and accessibility, collectively driving the overall growth and dynamism of the diabetes drug market.

5. Who are the key players operating in the diabetes drugs market?

• Some of the key market players operating in the diabetes drugs market include Novo Nordisk A/S, Eli Lilly and Company, AstraZeneca, Sanofi, Merck & Co., Inc., Novartis AG, Johnson & Johnson Services Inc., Takeda Pharmaceutical Company, Bayer AG, Pfizer Inc., Boehringer Ingelheim, MannKind Corporation, Bain Capital (Mitsubishi Tanabe Pharma Corporation (MTPC)), Gan & Lee Pharmaceuticals, Biocon Limited, TheracosBio, LLC, Sun Pharmaceutical Industries, Cadila Pharmaceuticals, Glenmark Pharmaceuticals, Hangzhou Sciwind Biosciences Co., Ltd., Lupin Limited, Torrent Pharmaceuticals, Astellas Pharma Inc., Lexicon Pharmaceuticals, Dong-A ST, Hanmi Pharmaceutical, and others.

Table of Contents

1. Diabetes Drugs Market Report Introduction

• 1.1 Scope of the Study
• 1.2 Market Segmentation
• 1.3 Market Assumption

2. Diabetes Drugs Market Executive Summary

• 2.1 Market at Glance

3. Diabetes Drugs Market Key Factors Analysis

• 3.1 Diabetes Drugs Market Drivers
  • 3.1.1 Increasing prevalence of diabetes and associated risk factors
  • 3.1.2 Rising awareness about diabetes and maintenance of blood sugar levels
  • 3.1.3 Increase in product development activities among the key market players
• 3.2 Diabetes Drugs Market Restraints and Challenges
  • 3.2.1 Risk of side effects and safety concerns
  • 3.2.2 Stringent regulations and reimbursement controls
• 3.3 Diabetes Drugs Market Opportunity
  • 3.3.1 Presence of a strong diabetes drug pipeline

4. Impact Analysis: AI, Geopolitical, Trade, and Economic Developments

5. Regulatory Analysis

• 5.1 The United States
• 5.2 Europe
• 5.3 Japan
• 5.4 China

6. Diabetes Drugs Market Porter's Five Forces Analysis

• 6.1 Bargaining Power of Suppliers
• 6.2 Bargaining Power of Consumers
• 6.3 Threat of New Entrants
• 6.4 Threat of Substitutes
• 6.5 Competitive Rivalry

7. Diabetes Drugs Market Assessment

• 7.1 By Drug Type
  • 7.1.1 Insulin
  • 7.1.2 Non-Insulin Drugs
  • 7.1.3 Combination Drugs
• 7.2 By Route of Administration
  • 7.2.1 Oral
  • 7.2.2 Intravenous
  • 7.2.3 Subcutaneous
• 7.3 By Distribution Channel
  • 7.3.1 Hospital and Retail Pharmacies
  • 7.3.2 Online Pharmacies
• 7.4 By Geography
  • 7.4.1 North America
    • 7.4.1.1 United States Diabetes Drugs Market Size in USD million (2023-2034)
    • 7.4.1.2 Canada Diabetes Drugs Market Size in USD million (2023-2034)
    • 7.4.1.3 Mexico Diabetes Drugs Market Size in USD million (2023-2034)
  • 7.4.2 Europe
    • 7.4.2.1 France Diabetes Drugs Market Size in USD million (2023-2034)
    • 7.4.2.2 Germany Diabetes Drugs Market Size in USD million (2023-2034)
    • 7.4.2.3 United Kingdom Diabetes Drugs Market Size in USD million (2023-2034)
    • 7.4.2.4 Italy Diabetes Drugs Market Size in USD million (2023-2034)
    • 7.4.2.5 Spain Diabetes Drugs Market Size in USD million (2023-2034)
    • 7.4.2.6 Rest of Europe Diabetes Drugs Market Size in USD million (2023-2034)
  • 7.4.3 Asia-Pacific
    • 7.4.3.1 China Diabetes Drugs Market Size in USD million (2023-2034)
    • 7.4.3.2 Japan Diabetes Drugs Market Size in USD million (2023-2034)
    • 7.4.3.3 India Diabetes Drugs Market Size in USD million (2023-2034)
    • 7.4.3.4 Australia Diabetes Drugs Market Size in USD million (2023-2034)
    • 7.4.3.5 South Korea Diabetes Drugs Market Size in USD million (2023-2034)
    • 7.4.3.6 Rest of Asia-Pacific Diabetes Drugs Market Size in USD million (2023-2034)
  • 7.4.4 Rest of the World (RoW)
    • 7.4.4.1 Middle East Diabetes Drugs Market Size in USD million (2023-2034)
    • 7.4.4.2 Africa Diabetes Drugs Market Size in USD million (2023-2034)
    • 7.4.4.3 South America Diabetes Drugs Market Size In USD Million (2023-2034)

8. Competitive Landscape

9. Startup Funding & Investment Trends

10. Diabetes Drugs Market Company and Product Profiles

• 10.1 Novo Nordisk A/S
  • 10.1.1 Company Overview
  • 10.1.2 Company Snapshot
  • 10.1.3 Financial Overview
  • 10.1.4 Product Listing
  • 10.1.5 Entropy
• 10.2 Eli Lilly and Company
  • 10.2.1 Company Overview
  • 10.2.2 Company Snapshot
  • 10.2.3 Financial Overview
  • 10.2.4 Product Listing
  • 10.2.5 Entropy
• 10.3 AstraZeneca
  • 10.3.1 Company Overview
  • 10.3.2 Company Snapshot
  • 10.3.3 Financial Overview
  • 10.3.4 Product Listing
  • 10.3.5 Entropy
• 10.4 Sanofi
  • 10.4.1 Company Overview
  • 10.4.2 Company Snapshot
  • 10.4.3 Financial Overview
  • 10.4.4 Product Listing
  • 10.4.5 Entropy
• 10.5 Merck & Co., Inc.
  • 10.5.1 Company Overview
  • 10.5.2 Company Snapshot
  • 10.5.3 Financial Overview
  • 10.5.4 Product Listing
  • 10.5.5 Entropy
• 10.6 Novartis AG
  • 10.6.1 Company Overview
  • 10.6.2 Company Snapshot
  • 10.6.3 Financial Overview
  • 10.6.4 Product Listing
  • 10.6.5 Entropy
• 10.7 Johnson & Johnson Services Inc.
  • 10.7.1 Company Overview
  • 10.7.2 Company Snapshot
  • 10.7.3 Financial Overview
  • 10.7.4 Product Listing
  • 10.7.5 Entropy
• 10.8 Takeda Pharmaceutical Company
  • 10.8.1 Company Overview
  • 10.8.2 Company Snapshot
  • 10.8.3 Financial Overview
  • 10.8.4 Product Listing
  • 10.8.5 Entropy
• 10.9 Bayer AG
  • 10.9.1 Company Overview
  • 10.9.2 Company Snapshot
  • 10.9.3 Financial Overview
  • 10.9.4 Product Listing
  • 10.9.5 Entropy
• 10.10 Pfizer Inc.
  • 10.10.1 Company Overview
  • 10.10.2 Company Snapshot
  • 10.10.3 Financial Overview
  • 10.10.4 Product Listing
  • 10.10.5 Entropy
• 10.11 Boehringer Ingelheim
  • 10.11.1 Company Overview
  • 10.11.2 Company Snapshot
  • 10.11.3 Financial Overview
  • 10.11.4 Product Listing
  • 10.11.5 Entropy
• 10.12 MannKind Corporation
  • 10.12.1 Company Overview
  • 10.12.2 Company Snapshot
  • 10.12.3 Financial Overview
  • 10.12.4 Product Listing
  • 10.12.5 Entropy
• 10.13 Bain Capital (Mitsubishi Tanabe Pharma Corporation (MTPC))
  • 10.13.1 Company Overview
  • 10.13.2 Company Snapshot
  • 10.13.3 Financial Overview
  • 10.13.4 Product Listing
  • 10.13.5 Entropy
• 10.14 Gan & Lee Pharmaceuticals
  • 10.14.1 Company Overview
  • 10.14.2 Company Snapshot
  • 10.14.3 Financial Overview
  • 10.14.4 Product Listing
  • 10.14.5 Entropy
• 10.15 Biocon Limited
  • 10.15.1 Company Overview
  • 10.15.2 Company Snapshot
  • 10.15.3 Financial Overview
  • 10.15.4 Product Listing
  • 10.15.5 Entropy
• 10.16 TheracosBio, LLC
  • 10.16.1 Company Overview
  • 10.16.2 Company Snapshot
  • 10.16.3 Financial Overview
  • 10.16.4 Product Listing
  • 10.16.5 Entropy
• 10.17 Sun Pharmaceutical Industries
  • 10.17.1 Company Overview
  • 10.17.2 Company Snapshot
  • 10.17.3 Financial Overview
  • 10.17.4 Product Listing
  • 10.17.5 Entropy
• 10.18 Cadila Pharmaceuticals
  • 10.18.1 Company Overview
  • 10.18.2 Company Snapshot
  • 10.18.3 Financial Overview
  • 10.18.4 Product Listing
  • 10.18.5 Entropy
• 10.19 Glenmark Pharmaceuticals
  • 10.19.1 Company Overview
  • 10.19.2 Company Snapshot
  • 10.19.3 Financial Overview
  • 10.19.4 Product Listing
  • 10.19.5 Entropy
• 10.20 Hangzhou Sciwind Biosciences Co., Ltd.
  • 10.20.1 Company Overview
  • 10.20.2 Company Snapshot
  • 10.20.3 Financial Overview
  • 10.20.4 Product Listing
  • 10.20.5 Entropy
• 10.21 Lupin Limited
  • 10.21.1 Company Overview
  • 10.21.2 Company Snapshot
  • 10.21.3 Financial Overview
  • 10.21.4 Product Listing
  • 10.21.5 Entropy
• 10.22 Torrent Pharmaceuticals
  • 10.22.1 Company Overview
  • 10.22.2 Company Snapshot
  • 10.22.3 Financial Overview
  • 10.22.4 Product Listing
  • 10.22.5 Entropy
• 10.23 Astellas Pharma Inc.
  • 10.23.1 Company Overview
  • 10.23.2 Company Snapshot
  • 10.23.3 Financial Overview
  • 10.23.4 Product Listing
  • 10.23.5 Entropy
• 10.24 Lexicon Pharmaceuticals
  • 10.24.1 Company Overview
  • 10.24.2 Company Snapshot
  • 10.24.3 Financial Overview
  • 10.24.4 Product Listing
  • 10.24.5 Entropy
• 10.25 Dong-A ST
  • 10.25.1 Company Overview
  • 10.25.2 Company Snapshot
  • 10.25.3 Financial Overview
  • 10.25.4 Product Listing
  • 10.25.5 Entropy
• 10.26 Hanmi Pharmaceutical.
  • 10.26.1 Company Overview
  • 10.26.2 Company Snapshot
  • 10.26.3 Financial Overview
  • 10.26.4 Product Listing
  • 10.26.5 Entropy

11. KOL Views

12. Project Approach

13. About DelveInsight

14. Disclaimer & Contact Us